Related Experiment Video
Updated: Jun 8, 2026
10:42
Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
Published on: May 13, 2016
Ethanolamine is a novel STAT-3 dependent cardioprotective agent
Roisin F Kelly1, Kim T Lamont, Sarin Somers
1Hatter Cardiovascular Research Institute, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. R.Kelly@uct.ac.za
Basic Research in Cardiology
|October 13, 2010
Summary
Ethanolamine protects the heart from ischemia/reperfusion injury by activating STAT-3. This protective effect was observed in mouse and rat hearts, highlighting a novel cardioprotective role for ethanolamine.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Biochemistry
Background:
- Ethanolamine is a naturally occurring biogenic amine involved in cellular processes.
- While known for brain protection against apoptosis, its role in cardiac health remains unclear.
- Signal transducer and activator of transcription 3 (STAT-3) is a key survival factor in heart injury.
Purpose of the Study:
- To investigate the potential cardioprotective effects of ethanolamine against ischemia/reperfusion (I/R) injury.
- To determine if ethanolamine exerts its effects through the activation of STAT-3 in the heart.
Main Methods:
- Isolated mouse and rat hearts were subjected to I/R injury with and without ethanolamine pre-treatment.
- Cardiomyocyte-specific STAT-3 knockout mice were used to assess the role of STAT-3.
- In vivo rat hearts were treated with sphingosine-1-phosphate and/or a FAAH inhibitor.
- Infarct size was quantified using triphenyltetrazolium chloride staining.
Main Results:
- Ethanolamine pre-treatment significantly reduced infarct size in both isolated mouse and rat hearts.
- This infarct-sparing effect of ethanolamine was abolished in hearts lacking cardiomyocyte-specific STAT-3.
- Ethanolamine administration led to increased nuclear phosphorylated STAT-3 levels.
Conclusions:
- Ethanolamine demonstrates a novel cardioprotective role against I/R injury.
- This protective mechanism is mediated through the activation of STAT-3 in cardiomyocytes.
- Ethanolamine represents a potential therapeutic target for mitigating cardiac damage.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:23Cardiopulmonary Resuscitation III: AED Use
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...